MOR03087: Additional Phase I/IIa data

Data from 15 evaluable relapsed or refractory MM patients previously treated with >=2 prior therapies including an immunomodulatory drug and a proteasome

Read the full 222 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE